Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 9/20 | 0.77 |
| ▸ | EGFR | P00533 | 14/20 | 0.73 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.63 |
| ▸ | RET | P07949 | 1/20 | 0.59 |
| ▸ | MST1R | Q04912 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4416987 | 0.96 | ERBB2 (0.75) | ERBB2EGFRERBB4RET | |
| SCHEMBL12743425 | 0.96 | ERBB2 (0.77) | ERBB2EGFR | |
| SCHEMBL120193 | 0.93 | ERBB2 (0.76) | ERBB2EGFRERBB4RETMST1R | |
| SCHEMBL29623446 | 0.93 | ERBB2 (0.76) | ERBB2EGFRERBB4RETMST1R | |
| SCHEMBL4422322 | 0.92 | ERBB2 (0.73) | ERBB2EGFRERBB4RETMST1R | |
| SCHEMBL12743434 | 0.92 | ERBB2 (0.75) | ERBB2EGFRERBB4RET | |
| SCHEMBL12743429 | 0.91 | ERBB2 (0.73) | ERBB2EGFRERBB4RETMST1R | |
| SCHEMBL1446101 | 0.90 | ERBB2 (0.72) | ERBB2EGFRERBB4RETMST1R | |
| SCHEMBL10285954 | 0.90 | EGFR (0.84) | ERBB2EGFRERBB4RET | |
| SCHEMBL12743433 | 0.89 | ERBB2 (0.74) | ERBB2EGFRERBB4RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8343982-B2 | Bicyclic heterocyclic compounds pharmaceutical compositions containing these compounds, their use and process for preparing the same | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2013-01-01 | — | — | US | disclosed |
| US-8343982-B2 | Bicyclic heterocyclic compounds pharmaceutical compositions containing these compounds, their use and process for preparing the same | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2013-01-01 | — | — | US | disclosed |
| EP-1492536-B1 | 4-(N-PHENYLAMINO)-QUINAZOLINES / QUINOLINES AS TYROSINE KINASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA (DE) | 2012-05-09 | — | — | EP | disclosed |
| US-20110077246-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESS FOR PREPARING THE SAME | BOEHRINGER INGELHEIM PHARMA GMBH & CO. (DE) | 2011-03-31 | — | — | US | disclosed |
| US-20110077246-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESS FOR PREPARING THE SAME | BOEHRINGER INGELHEIM PHARMA GMBH & CO. (DE) | 2011-03-31 | — | — | US | disclosed |
| EP-2298305-A1 | 4-(N-Phenylamino)-quinazolines/quinolines as inhibitors of tyrosine kinases | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2011-03-23 | — | — | EP | disclosed |
| US-7910731-B2 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2011-03-22 | — | — | US | disclosed |
| US-7910731-B2 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2011-03-22 | — | — | US | disclosed |
| US-20090036676-A1 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | HIMMELSBACH FRANK | 2009-02-05 | — | — | US | disclosed |
| US-20090036676-A1 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | HIMMELSBACH FRANK | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077246-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESS FOR PREPARING THE SAME | CYP11B2, CYP11B1, PKD1 | ERBB2 1199/4885EGFR 1254/4885ERBB4 2522/4885 |
| US-20090036676-A1 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | CYP11B2, CYP11B1, HPGD | ERBB2 1107/4885EGFR 1233/4885ERBB4 2422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.